ZURICH, March 4, 2026 /PRNewswire/ -- Fapon Biopharma today announced that Dr. Kaiqing Zhang, Ph.D., Associate Director of Business/Corporate Development, will deliver a company presentation at the 19 ...
Treatment with anti-CD19 bispecific T-cell engager and CAR T therapies can lead to T-cell exhaustion and treatment failure. Novartis AG’s first-in-class anti-CD19, anti-CD3 and anti-CD2 IgG-like ...
Immunotherapy. 2011;3(11):1303-1306. As discussed above, the proof-of-principle studies using both anti-CD3 antibodies (teplizumab and otelixizumab) showed effects on surrogate markers (C-peptide ...
(1) A chimeric antigen receptor (CAR) is a modular, synthetic receptor that endows T cells with different targeting abilities. Several emerging engineering approaches aim to improve the safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results